“It Changes Everything, and It Changes Nothing”: a Prospective, Mixed-Method Study of the Value of Genomic Sequencing for Parents of Children with Undiagnosed Rare Diseases.

Background While much recent literature has focused on patients’ and families’ perceptions of the value of genome-wide sequencing (GS, including exome and genome sequencing) for rare disease diagnosis, conceptual and methodological limitations remain. We sought to characterize expectations of, and longitudinal perspectives on, the value of GS and its outcomes for parents of pediatric rare disease patients.Methods From December 2021 through April 2024, we enrolled and followed parents of pediatric patients undergoing GS with pending results. Parents completed three in-depth interviews: at baseline, at return of results, and six months after return. Data were analyzed using both qualitative and quantitative methods.Results Thirty-six parents participated. Four key findings emerged: 1) at baseline, parents balanced expansive hope for a range of benefits from GS with tempered expectations; 2) parents of children who received a definitive diagnosis reported achieving many expected outcomes, but the ultimate value of these outcomes was shaped by personal values and contextual factors; 3) parents of children who did not receive a definitive diagnosis nonetheless achieved some of the outcomes they sought from GS through other means; and 4) parents’ perceptions of the outcomes of sequencing evolved over time in varying directions.Conclusions Our findings indicate that the current literature examining the value parents ultimately derive from GS for rare disease diagnosis may fail to address critical nuances in subjective perceptions of value. Better understanding this value requires clarification of theories of value underlying current measures, rigorous, comparative methods, and consideration of families’ specific values and preferences.

Authors

Institutions

Publication Details

Journal
AJOB Empirical Bioethics
Published
2026-11-19
DOI
https://doi.org/10.1080/23294515.2026.2756631
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

“It Changes Everything, and It Changes Nothing”: a Prospective, Mixed-Method Study of the Value of Genomic Sequencing for Parents of Children with Undiagnosed Rare Diseases.

Meghan C. Halley, Elizabeth R. Brassfield, Emily Gurwitz, AudreyStephannie Maghiro et al.
AJOB Empirical Bioethics
Genomics and Rare Diseases
article

“It Changes Everything, and It Changes Nothing”: a Prospective, Mixed-Method Study of the Value of Genomic Sequencing for Parents of Children with Undiagnosed Rare Diseases.

Meghan C. Halley, Elizabeth R. Brassfield, Emily Gurwitz, AudreyStephannie Maghiro, Alisha Giri, Emily M. Ostler, Ava Goumas, Charis O. Tang
article en

Abstract

Background While much recent literature has focused on patients’ and families’ perceptions of the value of genome-wide sequencing (GS, including exome and genome sequencing) for rare disease diagnosis, conceptual and methodological limitations remain. We sought to characterize expectations of, and longitudinal perspectives on, the value of GS and its outcomes for parents of pediatric rare disease patients.Methods From December 2021 through April 2024, we enrolled and followed parents of pediatric patients undergoing GS with pending results. Parents completed three in-depth interviews: at baseline, at return of results, and six months after return. Data were analyzed using both qualitative and quantitative methods.Results Thirty-six parents participated. Four key findings emerged: 1) at baseline, parents balanced expansive hope for a range of benefits from GS with tempered expectations; 2) parents of children who received a definitive diagnosis reported achieving many expected outcomes, but the ultimate value of these outcomes was shaped by personal values and contextual factors; 3) parents of children who did not receive a definitive diagnosis nonetheless achieved some of the outcomes they sought from GS through other means; and 4) parents’ perceptions of the outcomes of sequencing evolved over time in varying directions.Conclusions Our findings indicate that the current literature examining the value parents ultimately derive from GS for rare disease diagnosis may fail to address critical nuances in subjective perceptions of value. Better understanding this value requires clarification of theories of value underlying current measures, rigorous, comparative methods, and consideration of families’ specific values and preferences.

AJOB Empirical Bioethics
Stanford Medicine (US), Stanford University (US)
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon